title: [Stenting in superficial femoral artery and usCRP: Multicentric study SAFE in 255 patients].
abstract: OBJECTIVE
  To evaluate mid-term primary patency of the femoral artery stenting in correlation with usCRP level and characteristics of the population, morphological aspect of the lesions and interventional techniques.
  
  
  METHODS
  Patients were prospectively included in a multicenter study (18 centers in France) after stenting (SMART, Cordis Johnson & Johnson, Issy-les-Moulineaux, France) of the superficial femoral artery (SFA). Inclusion and exclusion criteria were based on recommendations and every day practice of the centers.
  
  
  RESULTS
  Thus 255 patients (183 men; mean age: 69 years; range 44-92) were included. Technical success of the SFA stenting was 100% without any complications and primary angiographic success 97%. usCRP level increased significantly (p < 0.05) between before and 24h after SFA stenting. In the subgroup of patients without initial inflammation (n = 157), usCRP increased significantly (p < 0.05) in the group of patient with initial thrombosis and additional intervention (graft, amputation, angioplasty on other arterial bed) in the same procedure compared to the remaining patients. Restenosis rate was 12.4% (26/209 patients) at 7 ± 2 months. Before stenting, usCRP level was not predictive of a restenosis, whereas after stenting, an increase of the 24h usCRP level was significantly higher in the subgroup of patient with an occlusion at mid-term (8 patients; p < 0.05).
  
  
  CONCLUSIONS
  This study demonstrated good patency at 7 months of SFA stenting with nitinol SMART with an increase of the usCRP level 24h after stenting in favour of the presence of an occlusion at mid-term follow-up.
authors.affiliation: CHRU de Lille, hôpital cardiologique, service de radiologie, 59037 Lille cedex, France. jpberegi@gmail.com
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Beregi
authors.forename: Bertrand
authors.initials: B
authors.lastname: Lehalle
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Cardon
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Pillet
authors.forename: Alain
authors.initials: A
authors.lastname: Chabanier
authors.forename: Maxime
authors.initials: M
authors.lastname: Sibé
authors.forename: Pascal
authors.initials: P
authors.lastname: Aubry
authors.forename: Patrice
authors.initials: P
authors.lastname: de Cassin
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Raffin
authors.forename: Bruno
authors.initials: B
authors.lastname: Lecointre
authors.forename: Hélène
authors.initials: H
authors.lastname: Vernhet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000497:Alloys; D000792:Angiography; D017130:Angioplasty / Q000379:methods*; D001157:Arterial Occlusive Diseases / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D002097:C-Reactive Protein / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007383:Intermittent Claudication / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D007511:Ischemia / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D018810:Magnetic Resonance Angiography; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011475:Prosthesis Failure; D012008:Recurrence; D012307:Risk Factors; D015607:Stents; D013927:Thrombosis / Q000097:blood; D014057:Tomography, X-Ray Computed; D014654:Vascular Patency / Q000502:physiology
chemical_list: D000497:Alloys; C013616:nitinol; D002097:C-Reactive Protein